KRTX - Health Care Company Bristol-Myers Squibb Announces Merger With Karuna Therapeutics | Benzinga
Bristol-Myers Squibb (NYSE:BMY) has announced a merger with Karuna Therapeutics (NASDAQ:KRTX) that is expected to be completed 2024-H1.
Under the terms of the agreement, Bristol-Myers Squibb has agreed to give Karuna Therapeutics $14.00 billion in cash in exchange for KRTX stock.
About The Companies Involved
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development.
Karuna Therapeutics ...